Literature DB >> 23257526

A case of slowly progressive type 1 diabetes with insulin independence maintained for 10 years with α-glucosidase inhibitor monotherapy.

Yuichiro Munakata1, Tetsuya Yamada, Kazuma Takahashi, Sohei Tsukita, Kei Takahashi, Shojiro Sawada, Junta Imai, Yasushi Ishigaki, Yoshitomo Oka, Hideki Katagiri.   

Abstract

Slowly Progressive Type 1 Diabetes (SPT1D) is characterized by the absence of insulin dependence at the onset of diabetes and persistent detection of islet cell autoantibodies. These patients with high titers of glutamic acid decarboxylase autoantibodies (GADA) are known to progress to insulin dependence within several years. Low-dose insulin injections have been reported to prevent or delay the decline of insulin secretion in SPT1D patients. We experienced the case of an SPT1D patient with preserved endogenous insulin secretion and good glycemic control achieved with α-glucosidase inhibitor (α-GI) treatment alone for 10 years despite having continuously elevated GADA titers. The details of this case suggest that α-GI treatment might have preventive effects on SPT1D progression.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23257526     DOI: 10.2169/internalmedicine.51.8123

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  2 in total

Review 1.  Molecular mechanisms in autoimmune type 1 diabetes: a critical review.

Authors:  Zhiguo Xie; Christopher Chang; Zhiguang Zhou
Journal:  Clin Rev Allergy Immunol       Date:  2014-10       Impact factor: 8.667

2.  Clinical and Genetic Characteristics of Non-Insulin-Requiring Glutamic Acid Decarboxylase (GAD) Autoantibody-Positive Diabetes: A Nationwide Survey in Japan.

Authors:  Junichi Yasui; Eiji Kawasaki; Shoichiro Tanaka; Takuya Awata; Hiroshi Ikegami; Akihisa Imagawa; Yasuko Uchigata; Haruhiko Osawa; Hiroshi Kajio; Yumiko Kawabata; Akira Shimada; Kazuma Takahashi; Kazuki Yasuda; Hisafumi Yasuda; Toshiaki Hanafusa; Tetsuro Kobayashi
Journal:  PLoS One       Date:  2016-05-13       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.